Delcath Systems DCTH CHEMOSAT — Product revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Delcath Systems in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Delcath Systems's chemosat — product revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Delcath Systems's CHEMOSAT — product revenue?
- Delcath Systems (DCTH) reported CHEMOSAT — product revenue of $1.75M in Q1 2026.
- How has Delcath Systems's CHEMOSAT — product revenue changed year-over-year?
- Delcath Systems's CHEMOSAT — product revenue decreased by 0.8% year-over-year, from $1.76M to $1.75M.
- What is the long-term trend for Delcath Systems's CHEMOSAT — product revenue?
- Over 2 years (2023 to 2025), Delcath Systems's CHEMOSAT — product revenue has grown at a 76.0% compound annual growth rate (CAGR), from $2.07M to $6.4M.
- What does CHEMOSAT — product revenue mean?
- This metric measures the total gross sales generated from the commercial distribution of a specific medical device or drug-device combination product within a defined reporting segment. It reflects the market adoption rate, pricing power, and commercial success of the product in treating its target patient demographic. Analyzing this revenue stream provides insight into the company's ability to transition from clinical development to sustainable commercialization and market penetration.